#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

Here’s the “ground­break­ing” da­ta from the prostate can­cer drug No­var­tis spent $2 bil­lion to ac­quire: The mol­e­cule hit every end­point in the Phase III tri­al, in­clud­ing ex­tend­ing pa­tient lives by 4 months com­pared to stan­dard of care.

“It’s strik­ing­ly pos­i­tive,” Oliv­er Sar­tor, a prostate can­cer ex­pert at Tu­lane who led the study, told End­points News. “Dur­ing the course of the tri­al, you nev­er re­al­ly know how things are shak­ing out, and I was very, very pleas­ant­ly sur­prised.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER